Dermavant Sciences’ $200 Million Financing

VISCHER acted as Swiss counsel to Dermavant in the transaction. Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here